Study Estimates Kidney Injury in Cancer Patients using Immunotherapy

Kidney damage is common in patients who take immunotherapy medications for treating their cancer, according to a study which appears in an upcoming issue of CJASN.

Immune checkpoint inhibitors are important medications that are effective at boosting the immune system's response against certain cancers, but they may sometimes cause severe side effects in organs such as the kidneys.

‘Patients using checkpoint point inhibitors for their cancer should maintain proper kidney health, as there is a high chance of acute kidney injury.’
Read More..

Tweet it Now

Use of proton pump inhibitors, which are commonly used to treat stomach ulcers or acid reflux, was associated with a higher risk of experiencing sustained AKI.

To determine the frequency, severity, and predictors of acute kidney injury (AKI) associated with these drugs, Meghan Sise, MD, Harish Seethapathy, MBBS (Massachusetts General Hospital), and their colleagues examined information on all patients who received immune checkpoint inhibitor therapy at their hospital from May 2011 to December 2016.

In the 1,016 patients the analysis, 169 patients (17%) experienced AKI, 82 patients (8%) experienced sustained AKI, and 30 patients (3%) had potential immune checkpoint inhibitor-related AKI. The first episode of sustained AKI occurred on average 106 days after patients initiated immune checkpoint inhibitor therapy.

Acute Renal (Kidney) Failure- Causes, Symptoms, Diagnosis, Treatment and Complications
Acute renal failure is the sudden cessation of the functioning of kidneys, that can be due to reduced renal blood flow, damage to renal tissues.

Sixteen patients (2%) experienced stage 3 sustained AKI and 4 patients required dialysis. Use of proton pump inhibitors, which are commonly used to treat stomach ulcers or acid reflux, was associated with a higher risk of experiencing sustained AKI.

"It is important for nephrologists and oncologists to recognize the incidence and factors that associate with AKI and checkpoint nephritis in patients receiving immunotherapy for cancer," said Dr. Sise.

"We believe that nephrologists are going to be increasingly called upon to determine the cause of AKI in patients on immune checkpoint inhibitors, and making an accurate diagnosis has huge implications for therapy for a patient's cancer treatment going forward."

An accompanying editorial highlights the strengths and limitations of the analysis and stresses the need for additional studies.

Source-Eurekalert